Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include ABI-SUVA for targeting HPV16+ induced malignancies, with head, and neck cancer as the primary indication is in Phase 2 randomized controlled trial. It also offers VB10.NEO, which is in Phase1b VB-N-02 trial; technology platform, which combines genes with desired properties to make novel compounds by creating a new code. Nykode Therapeutics AS was founded in 2006 and is headquartered in Oslo, Norway.
Frequently asked questions
What sector does Nykode Therapeutics AS (VACBF) operate in?
Nykode Therapeutics AS belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Nykode Therapeutics AS (VACBF) current stock price?
As of the latest data, Nykode Therapeutics AS stock price is $0.30, with a previous close of $0.45. Nykode Therapeutics AS lost -$0.16 in the last trading session, representing a -34.52% loss.
What is Nykode Therapeutics AS (VACBF) current market capitalization?
Nykode Therapeutics AS market cap is approximately 116.45 million.
What is Nykode Therapeutics AS (VACBF) Earnings Per Share (EPS)?
The trailing EPS is -$0.06.
What is Nykode Therapeutics AS (VACBF) EBITDA?
Nykode Therapeutics AS EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -6.66 million.
Does Nykode Therapeutics AS (VACBF) pay dividends?
Yes. Nykode Therapeutics AS pays annual dividends with an annualized yield of 33.02% and an estimated annual payout of $0.10 per share.
What is Nykode Therapeutics AS (VACBF) beta (volatility) score?
Nykode Therapeutics AS has a beta of 0.856, meaning its volatility is roughly in line with the market.
